Read More Pharma Industry News Is AFT Pharmaceuticals undervalued after NZ$208m in FY25 Revenue? What’s next for AFP stock AFT Pharmaceuticals posts NZ$208M record revenue in FY25. Find out why investors are eyeing its NZ$300M growth target despite short-term profit dips. byPallavi MadhirajuMay 22, 2025